-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

Benzinga·11/12/2026 13:01:34
Listen to the news
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $44 to $56.